Aerie Pharma (AERI) Misses Q3 EPS by 35c
Get Alerts AERI Hot Sheet
Join SI Premium – FREE
Aerie Pharma (NASDAQ: AERI) reported Q3 EPS of ($1.73), $0.35 worse than the analyst estimate of ($1.38). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $5.88 million.
As of September 30, 2018, Aerie had cash, cash equivalents and investments of $236.0 million.
For earnings history and earnings-related data on Aerie Pharma (AERI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Freedom Broker Downgrades RPC Inc. (RES) to Sell
- University Bancorp acquires remaining 20% of UIF for $15.2M
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share